GC Genome Corporation
Research GC Genome Corporation (340450.KQ) on Bullrun: market cap KRW 218.30B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker340450.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 218.30B
- Financial periodQ2 2026
- RevenueKRW 8.29B
- Net incomeKRW 780.81M
- Free cash flow-KRW 777.01M
- Gross margin45.0%
Valuation Snapshot
latest market cap is KRW 218.30B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 218.30B | n/a | n/a | n/a |
Dividend history
About GC Genome Corporation
GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is GC Genome Corporation's market cap?
GC Genome Corporation's market capitalization is KRW 218.30B.
What does GC Genome Corporation do?
GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing.